Trials / Completed
CompletedNCT02958085
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 22 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability, Pharmacokinetics (the exposure of the trial drug in the body) and Pharmacodynamics (the effect of the investigated drug on the body) of Multiple Dosing of NNC0174-0833 in Subjects with Obesity or Overweight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNC0174-0833 | Doses of NNC0174-0833, dosed either once daily or once weekly |
| DRUG | Placebo | Dosed either once daily or once weekly |
Timeline
- Start date
- 2016-11-04
- Primary completion
- 2018-01-24
- Completion
- 2018-01-24
- First posted
- 2016-11-08
- Last updated
- 2018-02-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02958085. Inclusion in this directory is not an endorsement.